Cargando…

All-cause 30- and 90-day inpatient readmission costs associated with 4 minimally invasive colon surgery approaches: A propensity-matched analysis using Medicare and commercial claims data

BACKGROUND: The purpose of this study is to assess which minimally invasive colon surgery approach may be associated with the least 30- and 90-day inpatient readmission costs from a payer perspective. METHODS: This retrospective claims analysis included adult Medicare and commercially insured benefi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sosa, Michelle P., McNicholas, Deirdre G., Bebla, Arbelina B., Needham, Keith A., Starker, Paul M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552086/
https://www.ncbi.nlm.nih.gov/pubmed/36237948
http://dx.doi.org/10.1016/j.sopen.2022.09.007
_version_ 1784806177135132672
author Sosa, Michelle P.
McNicholas, Deirdre G.
Bebla, Arbelina B.
Needham, Keith A.
Starker, Paul M.
author_facet Sosa, Michelle P.
McNicholas, Deirdre G.
Bebla, Arbelina B.
Needham, Keith A.
Starker, Paul M.
author_sort Sosa, Michelle P.
collection PubMed
description BACKGROUND: The purpose of this study is to assess which minimally invasive colon surgery approach may be associated with the least 30- and 90-day inpatient readmission costs from a payer perspective. METHODS: This retrospective claims analysis included adult Medicare and commercially insured beneficiaries who underwent minimally invasive sigmoid, left, or right colon surgery between January 2016 and December 2019. Two cohorts were created based on the use of near-infrared fluorescence (NIF) and were propensity-score matched 1 NIF:5 NoNIF. Four subgroups were then created based on the presence of robotics (R): NIF-NoR, NIF-R, NoNIF-R, and NoNIF-NoR. RESULTS: A total of 50,148 patients were identified, of which 165 (0.3%) indicated the use of NIF and 49,983 (99.7%) did not. After propensity score matching, 990 patients were included (NIF cohort: 165; NoNIF cohort: 825). Of the 165 NIF patients, 87 were robotic-assisted and 78 were conventional laparoscopy. Of the 825 NoNIF patients, 136 were robotic-assisted and 689 were conventional laparoscopy. Postindex inpatient readmission costs were significantly different between the NIF and NoNIF cohorts with the NIF cohort having the lowest 30- and 90-day postindex readmission costs. Postindex readmission costs were also significantly different across the 4 subgroups at 30 and 90 days, with the NIF-NoR group having the lowest postindex readmission costs (all P < .05). CONCLUSION: Using NIF without the robot during minimally invasive colon surgery is associated with the least 30- and 90-day inpatient readmission costs compared to the other 3 approaches. Hospitals may want to consider these potential cost savings when evaluating technologies for laparoscopic colon surgery. KEY MESSAGE: Near-infrared fluorescence (NIF) imaging without the robot during minimally invasive colon surgery may significantly save hospitals 30- and 90-day inpatient readmission costs compared to NIF with the robot, NoNIF with the robot, and NoNIF without the robot. This is important as hospitals may want to consider these cost findings in addition to capital equipment and disposable costs when evaluating technologies for laparoscopic colon surgery.
format Online
Article
Text
id pubmed-9552086
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95520862022-10-12 All-cause 30- and 90-day inpatient readmission costs associated with 4 minimally invasive colon surgery approaches: A propensity-matched analysis using Medicare and commercial claims data Sosa, Michelle P. McNicholas, Deirdre G. Bebla, Arbelina B. Needham, Keith A. Starker, Paul M. Surg Open Sci Research Paper BACKGROUND: The purpose of this study is to assess which minimally invasive colon surgery approach may be associated with the least 30- and 90-day inpatient readmission costs from a payer perspective. METHODS: This retrospective claims analysis included adult Medicare and commercially insured beneficiaries who underwent minimally invasive sigmoid, left, or right colon surgery between January 2016 and December 2019. Two cohorts were created based on the use of near-infrared fluorescence (NIF) and were propensity-score matched 1 NIF:5 NoNIF. Four subgroups were then created based on the presence of robotics (R): NIF-NoR, NIF-R, NoNIF-R, and NoNIF-NoR. RESULTS: A total of 50,148 patients were identified, of which 165 (0.3%) indicated the use of NIF and 49,983 (99.7%) did not. After propensity score matching, 990 patients were included (NIF cohort: 165; NoNIF cohort: 825). Of the 165 NIF patients, 87 were robotic-assisted and 78 were conventional laparoscopy. Of the 825 NoNIF patients, 136 were robotic-assisted and 689 were conventional laparoscopy. Postindex inpatient readmission costs were significantly different between the NIF and NoNIF cohorts with the NIF cohort having the lowest 30- and 90-day postindex readmission costs. Postindex readmission costs were also significantly different across the 4 subgroups at 30 and 90 days, with the NIF-NoR group having the lowest postindex readmission costs (all P < .05). CONCLUSION: Using NIF without the robot during minimally invasive colon surgery is associated with the least 30- and 90-day inpatient readmission costs compared to the other 3 approaches. Hospitals may want to consider these potential cost savings when evaluating technologies for laparoscopic colon surgery. KEY MESSAGE: Near-infrared fluorescence (NIF) imaging without the robot during minimally invasive colon surgery may significantly save hospitals 30- and 90-day inpatient readmission costs compared to NIF with the robot, NoNIF with the robot, and NoNIF without the robot. This is important as hospitals may want to consider these cost findings in addition to capital equipment and disposable costs when evaluating technologies for laparoscopic colon surgery. Elsevier 2022-09-25 /pmc/articles/PMC9552086/ /pubmed/36237948 http://dx.doi.org/10.1016/j.sopen.2022.09.007 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Paper
Sosa, Michelle P.
McNicholas, Deirdre G.
Bebla, Arbelina B.
Needham, Keith A.
Starker, Paul M.
All-cause 30- and 90-day inpatient readmission costs associated with 4 minimally invasive colon surgery approaches: A propensity-matched analysis using Medicare and commercial claims data
title All-cause 30- and 90-day inpatient readmission costs associated with 4 minimally invasive colon surgery approaches: A propensity-matched analysis using Medicare and commercial claims data
title_full All-cause 30- and 90-day inpatient readmission costs associated with 4 minimally invasive colon surgery approaches: A propensity-matched analysis using Medicare and commercial claims data
title_fullStr All-cause 30- and 90-day inpatient readmission costs associated with 4 minimally invasive colon surgery approaches: A propensity-matched analysis using Medicare and commercial claims data
title_full_unstemmed All-cause 30- and 90-day inpatient readmission costs associated with 4 minimally invasive colon surgery approaches: A propensity-matched analysis using Medicare and commercial claims data
title_short All-cause 30- and 90-day inpatient readmission costs associated with 4 minimally invasive colon surgery approaches: A propensity-matched analysis using Medicare and commercial claims data
title_sort all-cause 30- and 90-day inpatient readmission costs associated with 4 minimally invasive colon surgery approaches: a propensity-matched analysis using medicare and commercial claims data
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552086/
https://www.ncbi.nlm.nih.gov/pubmed/36237948
http://dx.doi.org/10.1016/j.sopen.2022.09.007
work_keys_str_mv AT sosamichellep allcause30and90dayinpatientreadmissioncostsassociatedwith4minimallyinvasivecolonsurgeryapproachesapropensitymatchedanalysisusingmedicareandcommercialclaimsdata
AT mcnicholasdeirdreg allcause30and90dayinpatientreadmissioncostsassociatedwith4minimallyinvasivecolonsurgeryapproachesapropensitymatchedanalysisusingmedicareandcommercialclaimsdata
AT beblaarbelinab allcause30and90dayinpatientreadmissioncostsassociatedwith4minimallyinvasivecolonsurgeryapproachesapropensitymatchedanalysisusingmedicareandcommercialclaimsdata
AT needhamkeitha allcause30and90dayinpatientreadmissioncostsassociatedwith4minimallyinvasivecolonsurgeryapproachesapropensitymatchedanalysisusingmedicareandcommercialclaimsdata
AT starkerpaulm allcause30and90dayinpatientreadmissioncostsassociatedwith4minimallyinvasivecolonsurgeryapproachesapropensitymatchedanalysisusingmedicareandcommercialclaimsdata